Réf. :HematoStat.net ; 2 (10) : R54 Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer […]
Bristol Myers Squibb annonce la publication au Journal Officiel de l’agrément à l’usage des collectivités et de l’inscription au remboursement par la sécurité sociale de trois nouveaux traitements dans les […]
Réf :HematoStat.net ; 2 (7) : V63 EORTC Quality of Life Group. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic […]
Réf :HematoStat.net ; 2 (7) : V62 Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio […]
Réf :HematoStat.net ; 2 (7) : V60 Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, Martinez-Calle N, […]
Réf :HematoStat.net ; 2 (7) : V59 Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Rigolin GM, Del Giudice I, […]
Réf :HematoStat.net ; 2 (7) : V58 Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, […]
Réf :HematoStat.net ; 2 (7) : V57 The CLL12 trial: ibrutinib vs. placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf […]
Réf. :HematoStat.net ; 2 (7) : R53 Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Al-Sawaf O, Zhang C, Lu T, Liao […]
Réf. :HematoStat.net ; 2 (7) : R52 Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized […]
editor’s pick
latest video
news via inbox
Nulla turp dis cursus. Integer liberos euismod pretium faucibua